Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 215 participants.
Also called NCT03482180
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 215 participants
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
- Registry
-
NCT03482180
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT03482180. Randomized; double masking; primary purpose treatment. Start 2016-05-04 (actual); primary completion 2017-05-16 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled
- Condition
- Dyslipidemias
- Intervention (Drug)
- KI1106 4g, QD
- Intervention (Drug)
- Atorvastatin Calcium 20mg, QD
- Lead sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct03482180- Content hash
6be066d3c8bba4d8a1385b54ad09dbd33fba65291dedc61d8b350c0fe8377b4b